Sarah Lessire

Sarah Lessire

Auto-generated profile, based on publicly available information

Sarah Lessire

Department of Anesthesiology, Namur Thrombosis and Hemostasis Center (NTHC), NAmur Research Institute for LIfe Sciences (NARILIS), Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2017 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
JDJonathan Douxfils
Jonathan Douxfils
WAW. Ageno
W. Ageno
CSC.‐M. Samama
C.‐M. Samama
SLS. Lessire
S. Lessire
HCH. Ten Cate
H. Ten Cate
FMF. Mullier
F. Mullier
Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral anticoagulants Summary One of the key benefits of the direct oral anticoagulants (DOACs) is that they do not require routine laboratory monitoring. Nevertheless, assessment of DOAC exposure and anticoagulant effects may become useful in various clinical scenarios. The five approved DOACs (apixaban, betrixaban, dabigatran etexilate, edoxaban and rivaroxaban) have different characteristics impacting assay selection and the interpretation of results. This article provides an updated overview on (i) which test to use (and their advantages and limitations), (ii) when to assay DOAC levels, (iii) how to interpret the results relating to bleeding risk, emergency situations and perioperative management, and (iv) what is the impact of DOACs on routine and specialized coagulation assays. Assays for anti‐Xa or anti‐IIa activity are the preferred methods when quantitative information is useful, although the situations in which to test for DOAC levels are still debated. Different reagent sensitivities and variabilities in laboratory calibrations impact assay results. International calibration standards for all specific tests for each DOAC are needed to reduce the inter‐laboratory variability and allow inter‐study comparisons. The impact of the DOACs on hemostasis testing may cause false‐positive or false‐negative results; however, these can be minimized by using specific assays and collecting blood samples at trough concentrations. Finally, prospective clinical trials are needed to validate the safety and efficacy of proposed laboratory thresholds in relation to clinical decisions. We offer recommendations on the tests to use for measuring DOACs and practical guidance on laboratory testing to help patient management and avoid diagnostic errors.

15 May 2017 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
VDVirginie Dubois
Virginie Dubois
ADAnne-Sophie Dincq
Anne-Sophie Dincq
JDJonathan Douxfils
Jonathan Douxfils
BIBrigitte Ickx
Brigitte Ickx
CSCharles-Marc Samama
Charles-Marc Samama
SLSarah Lessire
Sarah Lessire
Direct oral anticoagulants (DOACs) have been licensed worldwide for several years for various indications. Each year, 10–15% of patients on oral anticoagulants will undergo an invasive procedure and expert groups have issued several guidelines on perioperative management in such situations. The perioperative guidelines have undergone numerous updates as clinical experience of emergency management has increased and perioperative studies including measurement of residual anticoagulant levels have been published. The high inter-patient variability of DOAC plasma levels has challenged the traditional recommendation that perioperative DOAC interruption should be based only on the elimination half-life of DOACs, especially before invasive procedures carrying a high risk of bleeding. Furthermore, recent publications have highlighted the potential danger of heparin bridging use when DOACs are stopped before an invasive procedure. As antidotes are progressively becoming available to manage severe bleeding or urgent procedures in patients on DOACs, accurate laboratory tests have become the standard to guide their administration and their actions need to be well understood by clinicians. This review aims to provide a systematic approach to managing patients on DOACs, based on recent updates of various perioperative guidance, and highlighting the advantages and limits of recommendations based on pharmacokinetic properties and laboratory tests.

4 April 2018 in TH Open
Verified
Journal Article
Open access
PDF file
JFJulien Favresse
Julien Favresse
BLBenjamin Lardinois
Benjamin Lardinois
LSLina Sabor
Lina Sabor
BDBérangère Devalet
Bérangère Devalet
JVJulie Vandepapeliere
Julie Vandepapeliere
FMFrancois Mullier
Francois Mullier
The impact of direct oral anticoagulants (DOACs) on laboratory assays used for thrombophilia testing (e.g., antithrombin, protein S, protein C, lupus anticoagulant and activated protein-C resistance) is a well-known issue and may cause false-positive and -negative results. Therefore, the correct interpretation of tests that are performed in patients taking DOACs is mandatory to prevent misclassification and the subsequent clinical consequences. We aimed at evaluating the efficiency of a new and simple procedure (DOAC-Stop®; Haematex Research, Hornsby, Australia) to overcome the effect of all DOACs in real-life settings and to assess the percentage of erroneous results due to the presence of DOACs on thrombophilia screening tests. For this purpose, 135 DOAC-treated patients (38 apixaban, 40 dabigatran, 15 edoxaban, and 42 rivaroxaban) and 20 control patients were enrolled. A significant drop in apixaban, dabigatran, edoxaban, and rivaroxaban plasma concentrations following the DOAC-Stop® treatment was observed (74.8–8.2 ng/mL [p < 0.0001], 95.9–4.7 ng/mL [p < 0.0001], 102.1–8.8 ng/mL [p = 0.001], and 111.3–7.0 ng/mL [p < 0.0001], respectively). The DOAC-Stop® treatment was mostly effective to overcome the effect of DOACs on PTT-LA, dilute Russell's viper venom time (dRVVT) screen, and dRVVT confirm tests. Using our procedures, false-positive results due to DOACs were observed only with lupus anticoagulant tests (up to 75%) and fell to zero after the DOAC-Stop® procedure, regardless of the DOAC considered. In conclusion, the DOAC-Stop® adsorbent procedure appeared to be an effective and simple way to overcome the interference of DOAC on coagulation tests and should facilitate the interpretation of thrombophilia screening tests in patients taking DOACs.

1 July 2015 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
ADAnne-Sophie Dincq
Anne-Sophie Dincq
PHPaul Hjemdahl
Paul Hjemdahl
YRYuko Rönquist-Nii
Yuko Rönquist-Nii
APAnton Pohanka
Anton Pohanka
MGMaximilien Gourdin
Maximilien Gourdin
SLSarah Lessire
Sarah Lessire
Summary: The perioperative management of dabigatran is challenging, and recommendations based on activated partial thromboplastin time (aPTT) and thrombin time (TT) are unsatisfactory. Dedicated coagulation tests have limitations at plasma concentrations < 50 ng/ml. Therefore, a more sensitive test, which is available 24/7, is required. It was the aim of this study to investigate the performance of the Hemoclot Thrombin Inhibitors® LOW (HTI LOW) kit, a diluted thrombin time, and the STA® – ECA II (ECA-II) kit, a chromogenic variant of the ecarin clotting time, that were developed to measure low dabigatran concentrations, compared to reference dabigatran analysis by liquid chromatography tandem mass-spectrometry (LC-MS/MS). This study included 33 plasma samples from patients treated with dabigatran etexilate who had plasma concentrations < 200 ng/ml. HTI LOW and ECA-II were performed along with HTI, aPTT (STA®-C. K.Prest® and SynthasIL ®) and TT (STA® – Thrombin). All procedures were performed according to recommendations by the manufacturers. Linear (or curvilinear) correlations and Bland-Altman analyses were calculated. For free dabigatran concentrations < 50 ng/ml, the R2 of linear correlations were 0.69, 0.84 and 0.61, with HTI, HTI LOW and ECA-II, respectively. The R2 for TT, STA®-C. K.Prest® and SynthasIL® were 0.67, 0.42 and 0.15. For HTI, HTI LOW and ECA-II, Bland-Altman analyses revealed mean differences of –6 ng/ml (95 %CI: –25–14 ng/ml), 1 ng/ml (95 %CI: –18–19 ng/ml) and –1 ng/ml (95 %CI: –25–23 ng/ml), demonstrating that tests dedicated to measuring low concentrations are more accurate than HTI. In conclusion, the use of HTI LOW or ECA-II to assess low plasma dabigatran concentrations is supported by our findings.

7 May 2019 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
JDJonathan Douxfils
Jonathan Douxfils
LMLaure Morimont
Laure Morimont
CBCéline Bouvy
Céline Bouvy
MSMarie de Saint‐Hubert
Marie de Saint‐Hubert
BDBérangère Devalet
Bérangère Devalet
FMFrançois Mullier
François Mullier
Background Thrombin generation testing has been used to provide information on the coagulation phenotype of patients. The most used technique is the calibrated automated thrombogram (CAT) but it suffers from a lack of standardization preventing its implementation in routine. The ST Genesia is a new analyzer designed to assess thrombin generation based on the same principle as the CAT. Unlike the CAT system, the ST Genesia is a benchtop fully automated analyzer, able to perform the analyses individually and not by batch, with strict control of variables like temperature and volumes, ensuring, theoretically, a maximal reproducibility. Objectives This study aimed at assessing the performance of the STG®‐DrugScreen application on the ST Genesia analyzer. We also aimed at exploring stability of plasma samples after freezing and defining a reference normal range. Results Results demonstrated the excellent inter‐experiment precision of the ST Genesia and confirmed that the use of a reference plasma helps reducing the inter‐experiments variability. Stability revealed that plasma samples are stable for at least 11 months at ‐70°C or below, except for those containing low molecular weight heparins which have to be tested within 6 months. Freezing had no impact on the majority of thrombin generation parameters except on time‐to‐peak. Conclusions Our results suggest an easy implementation of thrombin generation with the use of ST Genesia in the routine laboratory. This will facilitate the design of multicentric studies and enable the establishment of reliable and evidence‐based thresholds, which may improve the management of patients treated with anticoagulants.

1 September 2015 in Thrombosis Research
Verified
Journal Article
Closed access
SLSarah Lessire
Sarah Lessire
JDJonathan Douxfils
Jonathan Douxfils
JBJustine Baudar
Justine Baudar
NBNicolas Bailly
Nicolas Bailly
ADAnne-Sophie Dincq
Anne-Sophie Dincq
FMFrancois Mullier
Francois Mullier